Track topics on Twitter Track topics that are important to you
Blood disorder therapeutics firm, Bioverativ, which was spun out from Biogen earlier this year, announced a research collaboration with Bicycle Therapeutics focused on developing and commercializing new treatments for haemophilia and sickle cell disease, based on the U.K. firm's Bicycle ® platform. Bicycles are bicyclic peptides that are designed to combine the benefits of antibodies, small molecules and peptides in one molecule, enabling high selectivity and affinity. Under terms of their partnership Bicycle will lead discovery and lead optimization activities thorugh to candidate selection for two product development programs, with Bioverativ heading subsequent preclinical development through to commercialization and marketing. Bicycle will receive a $10 million up front fee, and near-term R&D funding of $4.2 million. The firm could also earn up to $410 million in development, regulatoyr and commercialization milestones for planned products under the two programs, plus royalties on future sales. “We are constantly ...NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...